拉米夫定治疗慢性重型肝炎的疗效和预后观察  

Efficacy of Lamivudine in Treating Chronic Serious-type Hepatitis

作　　者：李晓欧[1] 过建春[1] 

机构地区：[1]杭州市第六人民医院,310014

出　　处：《中西医结合肝病杂志》2002年第3期134-135,共2页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:研究拉米夫定对慢性乙型重型肝炎的疗效、安全性及对预后的影响。方法:对慢性乙型重型肝炎患者采用常规治疗加口服拉米夫定100mg/d。连续30天,并与对照组比较。结果;拉米夫定组的好转率(75％)高于对照组(53％),P<0.05,且无明显不良反应,经随访,继续服用者肝功能基本正常,生活质量良好。结论:采用常规疗法联合拉米夫定治疗慢性重型肝炎为一种较好的治疗方案,可改善患者临床症状,促进肝功能恢复,提高患者的存活率。Objective: To study the efficacy, safety and effect to prognosis of Lamivudine in treating the chronic and fulminant virus hepatitis B patients. Methods: Oral Lamivudine tablet 100mg/d×30d with regular treatment were used to treat the chronic and fulminant virus hepatitis Bpatients and compared with the control group. Results: The efficacy rate of the group treated with Lamivudine (75% ) was higher than the control group (53%). P<0.05, without the obvious adverse reaction. Conducsions:The study shows that in consideration of lack of specific treatment now to the chronic and fulminant virus hepatitis B, it is a relatively good choice to treat with Lamivudine associated with the regular regular treatment. It can raise the rate of survival.

关 键 词：拉米夫定 乙型肝炎 慢性重型肝炎 预后 临床疗效 抗病毒治疗 

分 类 号：R575.1[医药卫生—消化系统]